OMITTED

What the news leaves out.

← Omitted front page

Amazon Recalls Over 112000 Bottles of Acetaminophen

4 sources · updated 2026-10-14
Left 25% Center 25% Right 50%
1 left · 1 center · 2 right

What happened

On September 18, Aurobindo Pharma USA, a New Jersey-based pharmaceutical company, initiated a voluntary recall of Amazon Extra Strength Acetaminophen 500 mg caplets after consumers reported discolored tablets. The Food and Drug Administration said the recall remains ongoing and covers more than 112,000 bottles: 14,640 of the 200-count size, 90,456 of the 500-count size, and 7,836 of the 1,000-count size, identified by listed lot numbers. The caplets were manufactured in India and distributed by Amazon.com Services LLC of Seattle. Amazon confirmed the action, with a spokesperson saying it was 'voluntarily recalling specific lots of Amazon Basic Care Extra Strength Pain Relief acetaminophen 500mg caplets due to reports of tablet discoloration in the affected lots' and that the recall was 'initiated in coordination with the manufacturer, Aurohealth, and the FDA.' The FDA did not identify the cause of the discoloration, describe any specific health risks, or say whether any injuries had been reported.
Sourcing check · Mostly on the record · 4 articles

2 of 4 articles cite a named source for the story. It started with unnamed sources; a named source appeared 13 hours later.

What these terms mean and how they're counted
On the record · names a source 2 of 4
On the record means the article cites a source by name for the story's main claim: a person, or an institution speaking officially, such as a company statement or a named agency's spokesperson. The opposite is an unnamed source. The count is how many of the counted articles cite at least one such source; the names are everyone named across them, each once however the articles spell it. Here: Aurobindo Pharma USA, Amazon, FDA, Food and Drug Administration (FDA) and Amazon spokesperson
Primary evidence · cites a document or data 1 of 4
Primary evidence means the article cites a record you could check yourself: a court filing or ruling, a dataset or report, a recording or transcript, an official statement or press release, market data. A quote is not a document. The count is how many articles cite one. Here: regulatory filing
Credits another outlet 0 of 4
The article says the story comes from another outlet's reporting (“first reported by Reuters”). Those articles relay the story; they are not independent confirmation. Here: Each article presents its own reporting.
Unnamed sources 0 of 4
The main claim is attributed to people who are not identified: “people familiar with the matter”, “officials said”. The count is how many articles do this.
How it developed
When the first report landed and whether it named anyone; when the first named source and the first document appeared. Here: First report Oct 13, 16:44 UTC by The Hill, with no named source. First named source 13 hours later, from Fox Business. First document the next day, from New York Post (regulatory filing).
Not counted 0
Opinion, analysis and video pieces, and articles too short to assess. Every count above is out of the counted articles. An article republished under a new headline is one article.
This is about who is cited, not whether the story is true. Each source below says what it names. How we count
Omitted — what each side leaves out

Unpacked

The recall is far larger than left-leaning coverage reports. Left-leaning coverage in The Hill describes thousands of bottles of acetaminophen sold on Amazon. Right-leaning coverage reports more than 112,000 bottles. The same right-leaning account names Aurobindo Pharma USA as the company that started the voluntary recall and says the FDA has not identified a cause. Without the larger figure, the event looks like a routine consumer notice rather than a major pullback of house-brand painkiller stock. The two sides also name the product differently. Left-leaning coverage says the bottles were "sold on Amazon," which reads as a marketplace listing. Right-leaning coverage instead presents Amazon Extra Strength acetaminophen as the retailer's own brand, made in India and distributed by Amazon. Neither side answers what the discoloration actually is, or whether a discolored caplet is unsafe to swallow.
Bottom line

The Hill's acetaminophen story never gets past thousands of bottles sold on Amazon. Fox Business puts the same recall at more than 112,000 bottles of Amazon Extra Strength and notes the FDA named neither a cause nor a health risk.

The receipts — 2 facts one side's coverage lacks
  • The FDA did not describe any specific health risks or say whether any injuries have been reported official statementin Fox Business · absent from left-leaning coverage
  • Affected lot numbers include ACD125040A (200-count), ACD124036A, ACD124030A, ACD124042A, ACD124048B, ACD125010A (500-count), and ACD124048A (1,000-count) contextin Fox Business · absent from left-leaning coverage
The Left View
The Hill framed the episode as a consumer alert about acetaminophen sold on Amazon, using the scale 'thousands of bottles' and attributing the action to recall notices in which consumers reported finding discolored tablets. That coverage centered the marketplace as the point of sale and did not make the manufacturer, production origin, or the FDA's silence on health risk the focus of the story.
The Right View
Fox Business framed the recall around its quantified scale—'more than 112,000 bottles'—and named Aurobindo Pharma USA/Aurohealth as the initiator, noting India manufacture and Amazon's on-the-record confirmation that the action was voluntary and coordinated with the manufacturer and FDA. It underlined that the agency 'did not describe any specific health risks or say whether any injuries have been reported,' and it placed this recall beside other marketplace product-safety items, including baby bath seats sold on Amazon and eye drops sold at Walgreens.
Our Take (balanced)
The left-leaning coverage's strongest argument is that this is a consumer-safety story about a common pain reliever sold through Amazon, supported by the recall notices' reports of discolored tablets. The right-leaning coverage's strongest argument is the fuller official record: a manufacturer-initiated voluntary recall of a counted inventory, Amazon's confirmation, India production, and the FDA's lack of stated cause, health risk, or injuries. The central unresolved tension is whether the episode is primarily about Amazon private-label quality control or an overseas manufacturer's defect—and whether unexplained discoloration implies a health hazard or a quality issue with no documented harm.

4 sources

More stories

The week's bottom lines, in your inbox

One email a week: the five stories that mattered and what they actually mean. Free.